A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy compared with chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015 Meeting Abstract


Authors: Tabernero, J.; Cohen, D.; Van Cutsem, E.; Janjigian, Y.; Bang, Y.; Qin, S.; Wang, A.; Hawk, N.; Shih, C.; Bhagia, P.; Shitara, K.
Abstract Title: A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy compared with chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015
Meeting Title: ESMO 23rd World Congress on Gastrointestinal Cancer
Journal Title: Annals of Oncology
Volume: 32
Issue: Suppl. 3
Meeting Dates: 2021 Jun 30-Jul 3
Meeting Location: Virtual
ISSN: 0923-7534
Publisher: Oxford University Press  
Date Published: 2021-07-01
Start Page: S151
End Page: S152
Language: English
ACCESSION: WOS:000670004200153
DOI: 10.1016/j.annonc.2021.05.209
PROVIDER: wos
Notes: Meeting Abstract: P-154 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Yelena Yuriy Janjigian
    394 Janjigian